SULT1C2

Summary

SULT1C2 (sulfotransferase family 1C member 2, HGNC:11456) is a protein-coding gene on chromosome 2q12.3, encoding Sulfotransferase 1C2 (O00338). Sulfotransferase that utilizes 3’-phospho-5’-adenylyl sulfate (PAPS) to catalyze the sulfate conjugation of phenolic compounds.

Sulfotransferase enzymes catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds. These cytosolic enzymes are different in their tissue distributions and substrate specificities. The gene structure (number and length of exons) is similar among family members. This gene encodes a protein that belongs to the SULT1 subfamily, responsible for transferring a sulfo moiety from PAPS to phenol-containing compounds. Two alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 6819 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 59 total
• Druggable target: yes
• MANE Select transcript: NM_001056

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11456
Approved symbol	SULT1C2
Name	sulfotransferase family 1C member 2
Location	2q12.3
Locus type	gene with protein product
Status	Approved
Aliases	ST1C1
Ensembl gene	ENSG00000198203
Ensembl biotype	protein_coding
OMIM	602385
Entrez	6819

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 9 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000251481, ENST00000326853, ENST00000409067, ENST00000409880, ENST00000437390, ENST00000438339, ENST00000442801, ENST00000492554, ENST00000495441, ENST00000900823, ENST00000939529, ENST00000947596

RefSeq mRNA: 2 — MANE Select: NM_001056 NM_001056, NM_176825

CCDS: CCDS2075, CCDS2076

Canonical transcript exons

ENST00000251481 — 8 exons

Exon	Start	End
ENSE00000772727	108294229	108294354
ENSE00000804415	108293647	108293818
ENSE00001269408	108300838	108300935
ENSE00001414539	108308352	108309915
ENSE00003559112	108304574	108304700
ENSE00003637914	108305415	108305595
ENSE00003676359	108305172	108305266
ENSE00003848372	108288895	108289070

Expression profiles

Bgee: expression breadth ubiquitous, 191 present calls, max score 98.13.

FANTOM5 (CAGE): breadth broad, TPM avg 1.3702 / max 113.7464, expressed in 434 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
21855	2.3818	331
21859	0.5954	273
21854	0.2855	147
21856	0.1655	74
21853	0.1091	36
21858	0.0969	42
21857	0.0642	22
202331	0.0536	19

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pylorus	UBERON:0001166	98.13	gold quality
nephron tubule	UBERON:0001231	97.13	gold quality
renal medulla	UBERON:0000362	96.63	gold quality
buccal mucosa cell	CL:0002336	96.53	gold quality
metanephros cortex	UBERON:0010533	96.23	gold quality
adult mammalian kidney	UBERON:0000082	95.81	gold quality
mucosa of stomach	UBERON:0001199	94.52	gold quality
kidney	UBERON:0002113	94.11	gold quality
kidney epithelium	UBERON:0004819	93.73	gold quality
cortex of kidney	UBERON:0001225	93.21	gold quality
renal glomerulus	UBERON:0000074	91.95	gold quality
corpus epididymis	UBERON:0004359	91.41	gold quality
metanephric glomerulus	UBERON:0004736	90.96	gold quality
caput epididymis	UBERON:0004358	90.93	gold quality
left lobe of thyroid gland	UBERON:0001120	89.45	gold quality
thyroid gland	UBERON:0002046	89.33	gold quality
right lobe of thyroid gland	UBERON:0001119	88.99	gold quality
duodenum	UBERON:0002114	88.08	gold quality
metanephros	UBERON:0000081	88.01	gold quality
pancreatic ductal cell	CL:0002079	87.82	silver quality
cardia of stomach	UBERON:0001162	87.11	gold quality
stomach	UBERON:0000945	86.37	gold quality
body of stomach	UBERON:0001161	86.23	gold quality
jejunal mucosa	UBERON:0000399	84.80	gold quality
choroid plexus epithelium	UBERON:0003911	81.64	gold quality
right uterine tube	UBERON:0001302	80.24	gold quality
pigmented layer of retina	UBERON:0001782	79.05	gold quality
gall bladder	UBERON:0002110	78.87	gold quality
adult organism	UBERON:0007023	78.70	gold quality
epithelial cell of pancreas	CL:0000083	78.10	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-81383	yes	166.12
E-ANND-3	yes	7.44

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FLCN, NR1H3, TFE3, VDR

miRNA regulators (miRDB)

77 targeting SULT1C2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-3913-5P	99.78	67.26	968
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-1825	99.72	68.11	1089
HSA-MIR-4499	99.62	67.29	1470
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-3122	99.50	66.33	821
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-4325	99.49	72.20	1342
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-4786-3P	99.36	68.35	1390

Literature-anchored findings (GeneRIF, showing 5)

• gene resequencing and functional genomic studies (PMID:11740338)
• crystal structures of two members of SULT1 family, SULT1B1 and SULT1C1, both in complex with the product of the PAPS cofactor, adenosine-3-5-diphosphate (PAP). (PMID:16804942)
• Our findings are the first to characterize the regulation of human SULT1C2 and SULT1C3 expression by several transcription factor activators. (PMID:24335393)
• Vitamin D receptor can interact directly with the SULT1C2 VDRE sequence to transcriptionally regulation SULT1C2 expression in colorectal tumor cells. (PMID:27130351)
• The Sulfotransferase SULT1C2 Is Epigenetically Activated and Transcriptionally Induced by Tobacco Exposure and Is Associated with Patient Outcome in Lung Adenocarcinoma. (PMID:35010676)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
mus_musculus	Sult1c2	ENSMUSG00000023122
rattus_norvegicus	Sult1c2a	ENSRNOG00000042111
rattus_norvegicus	LOC120094625	ENSRNOG00000065530
rattus_norvegicus	Sult1c2	ENSRNOG00000067413
rattus_norvegicus	Sult1c2al1	ENSRNOG00000068175
rattus_norvegicus	Sult1c2al1	ENSRNOG00000075356
rattus_norvegicus		ENSRNOG00000082870
rattus_norvegicus		ENSRNOG00000084902
drosophila_melanogaster	St4	FBGN0033887
drosophila_melanogaster	St1	FBGN0034887
drosophila_melanogaster	St3	FBGN0265052

Paralogs (12): SULT2B1 (ENSG00000088002), SULT2A1 (ENSG00000105398), SULT1E1 (ENSG00000109193), SULT4A1 (ENSG00000130540), SULT6B1 (ENSG00000138068), SULT1B1 (ENSG00000173597), SULT1C3 (ENSG00000196228), SULT1A1 (ENSG00000196502), SULT1A2 (ENSG00000197165), SULT1C4 (ENSG00000198075), SULT1A4 (ENSG00000213648), SULT1A3 (ENSG00000261052)

Protein

Protein identifiers

Sulfotransferase 1C2 — O00338 (reviewed: O00338)

Alternative names: Sulfotransferase 1C1, humSULTC2

All UniProt accessions (6): B4DLP0, B8ZZF7, C9JSR0, O00338, H7BZ17, H7C420

UniProt curated annotations — full annotation on UniProt →

Function. Sulfotransferase that utilizes 3’-phospho-5’-adenylyl sulfate (PAPS) to catalyze the sulfate conjugation of phenolic compounds. Does not transfer sulfate to steroids, dopamine, acetaminophen, or alpha-naphthol. Except in mitochondria, where it can add sulfate to cholesterol producing cholesterol sulfate, which alters mitochondrial membrane organization, and impacts protein complex mobility increasing state-III respiration, thereby modulating mitochondrial respiration. Catalyzes the sulfation of the carcinogenic N-hydroxy-2-acetylaminofluorene leading to highly reactive intermediates capable of forming DNA adducts, potentially resulting in mutagenesis.

Subcellular location. Cytoplasm. Lysosome. Mitochondrion.

Tissue specificity. Found in adult stomach, kidney and thyroid gland, and in fetal kidney and liver.

Similarity. Belongs to the sulfotransferase 1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
O00338-1	Short	yes
O00338-2	Long

RefSeq proteins (2): NP_001047, NP_789795 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000863	Sulfotransferase_dom	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00685

Catalyzed reactions (Rhea), 2 shown:

• a phenol + 3’-phosphoadenylyl sulfate = an aryl sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:12164)
• cholesterol + 3’-phosphoadenylyl sulfate = cholesterol sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:52368)

UniProt features (37 total): helix 14, binding site 7, strand 6, sequence variant 3, modified residue 2, turn 2, chain 1, active site 1, splice variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3BFX	X-RAY DIFFRACTION	1.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00338-F1	95.68	0.95

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 109 (proton acceptor)

Ligand- & substrate-binding residues (7): 49–54; 107–109; 131; 139; 194; 228–233; 256–260

Post-translational modifications (2): 254, 139

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-156584	Cytosolic sulfonation of small molecules
R-HSA-1430728	Metabolism
R-HSA-156580	Phase II - Conjugation of compounds
R-HSA-211859	Biological oxidations

MSigDB gene sets: 101 (showing top): REACTOME_BIOLOGICAL_OXIDATIONS, chr2q12, GOBP_SULFATION, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, CADWELL_ATG16L1_TARGETS_DN, MODULE_99, LIAO_METASTASIS, FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN, BASAKI_YBX1_TARGETS_DN, GRUETZMANN_PANCREATIC_CANCER_UP, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN, HAN_SATB1_TARGETS_DN, REACTOME_CYTOSOLIC_SULFONATION_OF_SMALL_MOLECULES, GOMF_ARYL_SULFOTRANSFERASE_ACTIVITY, REACTOME_PHASE_II_CONJUGATION_OF_COMPOUNDS

GO Biological Process (2): amine metabolic process (GO:0009308), sulfation (GO:0051923)

GO Molecular Function (5): aryl sulfotransferase activity (GO:0004062), sulfotransferase activity (GO:0008146), cholesterol sulfotransferase activity (GO:0051922), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (4): cytoplasm (GO:0005737), mitochondrion (GO:0005739), lysosome (GO:0005764), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Phase II - Conjugation of compounds	1
Biological oxidations	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cytoplasm	2
metabolic process	1
sulfur compound metabolic process	1
sulfotransferase activity	1
transferase activity, transferring sulphur-containing groups	1
alcohol sulfotransferase activity	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
intracellular membrane-bounded organelle	1
lytic vacuole	1

Protein interactions and networks

STRING

572 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SULT1C2	CYP4B1	P13584	514
SULT1C2	UGT1A10	Q9HAW8	449
SULT1C2	TMEM232	C9JQI7	443
SULT1C2	SULT1A3	P0DMM9	427
SULT1C2	SULT1A1	P50225	418
SULT1C2	UGT1A7	Q9HAW7	411
SULT1C2	UGT1A4	P22310	410
SULT1C2	UGT1A8	Q9HAW9	409
SULT1C2	UGT1A1	P22309	408
SULT1C2	VNN2	O95498	398
SULT1C2	UGT1A6	P19224	397
SULT1C2	DUOXA1	Q1HG43	394
SULT1C2	CHRNA4	P43681	392
SULT1C2	PAPSS2	O95340	390
SULT1C2	RECQL4	O94761	372
SULT1C2	MMP12	P39900	372

IntAct

19 interactions, top by confidence:

A	B	Type	Score
SULT1A1	SULT2B1	psi-mi:“MI:0914”(association)	0.830
SULT1C2	SULT1C4	psi-mi:“MI:0914”(association)	0.530
SULT1C2	TINF2	psi-mi:“MI:0915”(physical association)	0.510
SULT1C2	SULT2B1	psi-mi:“MI:0915”(physical association)	0.400
SULT1C2	TERF1	psi-mi:“MI:0915”(physical association)	0.370
SULT1C2	ACD	psi-mi:“MI:0915”(physical association)	0.370
POT1	SULT1C2	psi-mi:“MI:0915”(physical association)	0.370
SULT1C2	HLTF	psi-mi:“MI:0915”(physical association)	0.370
RASGRP3	SULT1C2	psi-mi:“MI:0915”(physical association)	0.370
POLL	SULT1C2	psi-mi:“MI:0914”(association)	0.350
SULT1C2		psi-mi:“MI:0914”(association)	0.350
OTULIN	SULT1C2	psi-mi:“MI:0914”(association)	0.350
SLC25A6	SULT1C2	psi-mi:“MI:0914”(association)	0.350
SULT1A2	SULT2B1	psi-mi:“MI:0914”(association)	0.350
SULT4A1	SULT2B1	psi-mi:“MI:0914”(association)	0.350
SULT1A3	SULT2B1	psi-mi:“MI:0914”(association)	0.350
TINF2	SULT1C2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (29): SULT1C2 (Affinity Capture-MS), SULT1A1 (Affinity Capture-MS), SULT1C4 (Affinity Capture-MS), SULT1A1 (Affinity Capture-MS), SULT1C2 (Affinity Capture-MS), SULT1C4 (Affinity Capture-MS), SULT1A3 (Affinity Capture-MS), SULT1C2 (Affinity Capture-MS), SULT1C2 (Affinity Capture-MS), SULT1C2 (Affinity Capture-MS), SULT1A1 (Affinity Capture-MS), SULT1C4 (Affinity Capture-MS), SULT1C2 (Affinity Capture-MS), SULT1A3 (Affinity Capture-MS), SULT1C2 (Affinity Capture-MS)

ESM2 similar proteins: A0A173GP47, A0A1L8HV70, A0A2K5X3B6, B2RVI8, F1QYJ6, G3V9R3, O00338, O43704, O46503, O75897, P0CC03, P15709, P17988, P19217, P22789, P27707, P46560, P48769, P49887, P49888, P49891, P50234, P50235, P50236, P50237, P52840, P52841, P52843, P52844, P52847, Q06520, Q3T0Y3, Q3UZZ6, Q5ZJM7, Q6IMI4, Q6IMI6, Q6PH37, Q6WG17, Q6WG18, Q7T2V2

Diamond homologs: A0A173GP47, A0A2K5X3B6, G3V9R3, O00338, O35400, O43704, O46503, O46640, O75897, P0DMM9, P0DMN0, P19217, P49887, P49888, P49891, P50236, P50237, P52839, P52840, P52842, P52844, P52847, P63046, P63047, Q29476, Q3T0Y3, Q3UZZ6, Q6IMI6, Q80VR3, Q8BGL3, Q8JG30, Q95JD5, Q9BR01, Q9C9D0, Q9D939, Q9FZ80, Q9QWG7, Q9WUW8, Q9WUW9, B2RVI8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 15 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Cytosolic sulfonation of small molecules	6	207.6×	7e-12
Phase II - Conjugation of compounds	5	92.8×	3e-08
Biological oxidations	5	43.3×	5e-07

GO biological processes:

GO term	Partners	Fold	FDR
sulfation	6	421.3×	1e-13
3’-phosphoadenosine 5’-phosphosulfate metabolic process	5	374.5×	4e-11

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	4
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

889 predictions. Top by Δscore:

Variant	Effect	Δscore
2:108293643:ATAG:A	acceptor_gain	1.0000
2:108293643:ATAGG:A	acceptor_gain	1.0000
2:108293644:T:G	acceptor_gain	1.0000
2:108293644:TAG:T	acceptor_loss	1.0000
2:108293645:A:AG	acceptor_gain	1.0000
2:108293645:A:C	acceptor_loss	1.0000
2:108293645:AG:A	acceptor_gain	1.0000
2:108293645:AGG:A	acceptor_gain	1.0000
2:108293646:G:GC	acceptor_gain	1.0000
2:108293646:GG:G	acceptor_gain	1.0000
2:108293646:GGG:G	acceptor_gain	1.0000
2:108293646:GGGA:G	acceptor_gain	1.0000
2:108293646:GGGAC:G	acceptor_gain	1.0000
2:108294219:T:TA	acceptor_gain	1.0000
2:108305170:A:AG	acceptor_gain	1.0000
2:108305170:AGT:A	acceptor_gain	1.0000
2:108305171:G:GA	acceptor_gain	1.0000
2:108305171:GTG:G	acceptor_gain	1.0000
2:108293643:A:AG	acceptor_gain	0.9900
2:108293816:C:T	donor_gain	0.9900
2:108294351:TCTGG:T	donor_loss	0.9900
2:108294353:TGG:T	donor_loss	0.9900
2:108294355:GT:G	donor_loss	0.9900
2:108294356:T:A	donor_loss	0.9900
2:108294357:GAGA:G	donor_loss	0.9900
2:108304572:A:AG	acceptor_gain	0.9900
2:108304573:G:GG	acceptor_gain	0.9900
2:108305171:GT:G	acceptor_gain	0.9900
2:108305171:GTGGT:G	acceptor_gain	0.9900
2:108305263:GAGG:G	donor_gain	0.9900

AlphaMissense

1997 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:108293813:A:T	K49I	0.991
2:108293814:A:C	K49N	0.990
2:108293814:A:T	K49N	0.990
2:108304600:A:C	K134N	0.988
2:108304600:A:T	K134N	0.988
2:108304601:G:C	D135H	0.988
2:108305186:T:A	W173R	0.987
2:108305186:T:C	W173R	0.987
2:108305207:T:A	W180R	0.986
2:108305207:T:C	W180R	0.986
2:108305583:T:C	F256L	0.985
2:108305585:C:A	F256L	0.985
2:108305585:C:G	F256L	0.985
2:108293818:G:T	G51W	0.984
2:108294229:G:T	G51V	0.983
2:108304599:A:T	K134I	0.983
2:108304625:T:C	F143L	0.983
2:108304627:C:A	F143L	0.983
2:108304627:C:G	F143L	0.983
2:108305591:A:C	R258S	0.982
2:108305591:A:T	R258S	0.982
2:108308366:T:A	W265R	0.982
2:108308366:T:C	W265R	0.982
2:108305448:T:C	F211L	0.981
2:108305450:C:A	F211L	0.981
2:108305450:C:G	F211L	0.981
2:108293802:C:G	C45W	0.979
2:108300885:C:G	H109D	0.979
2:108304590:G:C	R131P	0.979
2:108293792:T:C	L42P	0.978

dbSNP variants (sampled 300 via entrez): RS1000066197 (2:108301815 T>C,G), RS1000094579 (2:108292044 C>T), RS1000165224 (2:108310353 C>T), RS1000258913 (2:108288837 G>A), RS1000299760 (2:108289090 G>T), RS1000325125 (2:108309573 A>T), RS1000440001 (2:108303859 T>A,C), RS1000548984 (2:108287075 G>A), RS1000801463 (2:108292996 T>C), RS1000828520 (2:108299478 T>C), RS1000927210 (2:108307882 C>G), RS1000955533 (2:108300116 T>C,G), RS1001128909 (2:108293256 C>T), RS1001246132 (2:108302308 C>T), RS1001414189 (2:108305473 C>T)

Disease associations

OMIM: gene MIM:602385 | disease phenotypes: MIM:158580, MIM:617143

GenCC curated gene-disease

Mondo (2): neuronopathy, distal hereditary motor, type 7A (MONDO:0008024), congenital myasthenic syndrome 20 (MONDO:0014939)

Orphanet (1): Distal hereditary motor neuropathy type 7 (Orphanet:139589)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST002931_10	Aluminium levels	5.000000e-07
GCST003476_3	Eyebrow thickness	1.000000e-07
GCST003854_6	Gut microbiota (functional units)	2.000000e-08
GCST011039_7	Parkinson’s disease progression (composite)	4.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007874	gut microbiome measurement
EFO:0008336	disease progression measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C563562	Neuropathy, Distal Hereditary Motor, Type VIIA (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1743295 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, affects cotreatment, increases expression	8
Benzo(a)pyrene	decreases expression, increases methylation, affects methylation	4
trichostatin A	affects cotreatment, increases expression	3
Cyclosporine	decreases expression	3
entinostat	increases expression, affects cotreatment	2
belinostat	decreases expression, increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Aflatoxin B1	affects expression, increases methylation	2
aristolochic acid I	increases expression	1
potassium perchlorate	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
N-hydroxy-4-aminobiphenyl	increases sulfation	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
enilconazole	increases expression	1
2-amino-3-methyl-9H-pyrido(2,3-b)indole	increases activity	1
butyraldehyde	decreases expression	1
catechol	increases sulfation	1
caffeic acid	increases sulfation	1
pentanal	decreases expression	1
1-hydroxymethylpyrene	affects cotreatment, increases activity	1
fipronil	affects cotreatment, increases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	increases expression	1
Arsenic Trioxide	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1743307	ADMET	Major substrate of human cytosolic sulfotransferase SULT1C2	Casarett and Doull’s Toxicology The Basic Science of Poisons, 7th edition

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.